Molly Burich, MS, head of public policy at Boehringer Ingelheim, discusses the why there currently are no biosimilars with an interchangeability designation during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California..
Molly Burich, MS, is the head of public policy at Boehringer Ingelheim.
So far, there are no interchangeable biosimilars. Why is that?
The reason why we don't have any interchangeable biosimilars yet is because all that are launched are on the medical benefit side, meaning they're administered by the physician. And without that pharmacy interplay, there's really no need to have an interchangeability designation because that really is the primary goal of that designation, is to allow for that. When a physician is managing their own inventory and managing the switch, there is no pharmacy interaction. So, we haven't seen interchangeable[s] yet because, right now, we don't have any pharmacy benefit—approved biosimilars.